Cytel Researcher Discusses Deciding Between Progress Free Survival and Overall Survival Endpoints in Clinical Trials

Determining whether to use progress free survival (PFS) or overall survival (OS) in clinical trials is an important yet challenging decision for clinical trial sponsors. Dr. Esha Senchaudhuri at Cytel discusses the key differences between the two approaches and how Cytel’s decision-making platform can assist researchers in picking the appropriate endpoint.

“Most sponsors use PFS when trying to secure regulatory approval, and OS for market approval and market access. Building clinical trial designs that optimize across both has historically proven challenging, but new technology like Cytel’s Solara has also paved the way for new methods to find these potent designs.” Read more here.

(Source: Esha Senchaudhuri, Cytel, 9/8/21)